Vivo Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Vivo Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-856,008	Closed	-$10.5M	–	46
2023 Q4	$10.5M	Hold	856,008	–	–	0.86%	24
2023 Q3	$8.24M	Hold	856,008	–	–	0.9%	28
2023 Q2	$7.7M	Hold	856,008	–	–	0.53%	27
2023 Q1	$6.73M	Hold	856,008	–	–	0.47%	27
2022 Q4	$5.79M	Sell	856,008 -677,551	-44%	-$3.63M	0.67%	30
2022 Q3	$22.3M	Hold	1,533,559	–	–	2.46%	15
2022 Q2	$15.1M	Hold	1,533,559	–	–	1.52%	14
2022 Q1	$22.6M	Hold	1,533,559	–	–	1.56%	13
2021 Q4	$20.3M	Sell	1,533,559 -108,354	-7%	-$1.72M	1.22%	18
2021 Q3	$28.7M	Sell	1,641,913 -221,383	-12%	-$4.49M	1.29%	19
2021 Q2	$44.6M	Hold	1,863,296	–	–	1.93%	11
2021 Q1	$47.9M	Buy	1,863,296 +245,000	+15%	+$6.44M	1.68%	14
2020 Q4	$30.7M	Buy	1,618,296 +141,500	+10%	+$2.43M	1.37%	16
2020 Q3	$18.6M	Hold	1,476,796	–	–	1.07%	24
2020 Q2	$17.9M	Hold	1,476,796	–	–	1.28%	20
2020 Q1	$11.3M	Buy	+1,476,796	New	+$19.9M	1.02%	30
2019 Q3	–	Sell	-1,359,149	Closed	-$30.1M	–	20
2019 Q2	$30.1M	Hold	1,359,149	–	–	2.82%	10
2019 Q1	$38.9M	Hold	1,359,149	–	–	3.88%	5
2018 Q4	$26.8M	Hold	1,359,149	–	–	3.43%	7
2018 Q3	$30.1M	Buy	1,359,149 +1,058,824	+353%	+$14.3M	3.03%	11
2018 Q2	$2.44M	Hold	300,325	–	–	0.31%	36
2018 Q1	$2.85M	Hold	300,325	–	–	0.4%	30
2017 Q4	$2.93M	Hold	300,325	–	–	0.63%	24
2017 Q3	$2.02M	Buy	+300,325	New	+$2.14M	0.41%	27
2017 Q2	–	Sell	-300,325	Closed	-$2.35M	–	27
2017 Q1	$2.35M	Hold	300,325	–	–	0.69%	19
2016 Q4	$2.12M	Sell	300,325 -1	-0%	-$7	0.7%	19
2016 Q3	$1.93M	Hold	300,326	–	–	0.6%	17
2016 Q2	$2.77M	Hold	300,326	–	–	0.76%	16
2016 Q1	$2.69M	Buy	+300,326	New	+$5.38M	0.68%	18

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vivo Capital's KALV Position: Q1 2024 in Review

Vivo Capital sold out of KalVista Pharmaceuticals (KALV) in Q1 2024, closing a stake of 856,008 shares — an estimated $10.5M sold.

Vivo Capital first reported a position in KALV in Q1 2016 and held it in 29 quarters. The position peaked at $47.9M in Q1 2021. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2024.

Vivo Capital reported no remaining KalVista Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Vivo Capital sold 856,008 KalVista Pharmaceuticals shares in Q1 2024, an estimated $10.5M.
Vivo Capital first reported a position in KalVista Pharmaceuticals in Q1 2016 and held it in 29 quarters.
Vivo Capital's KalVista Pharmaceuticals position peaked at $47.9M in Q1 2021.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2024.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.